Novosteo Platform

Platform

Novosteo has a precise drug-targeting platform that allows us to take small molecules, peptides or large molecules and deliver them directly to the site of disease or injury.

PAYLOAD

  • Anabolic
  • Chemotherapy
  • Radionuclide
  • Antibiotic

LINKER

  • Fixed or cleavable

TARGETING LIGAND

  • High affinity
  • High specificity
  • Biocompatible

Precise
Therapeutic
Targeting

Osteosarcoma &
Bone Metastases
Fracture
Infection

How It Works: NOV004

We connect bone-specific targeting molecules to approved drugs, biologics or radionuclides via small biological linker molecules. The result is the delivery of the proven therapeutic payload directly to the site of disease or injury.
NOV004 delivers an anabolic that accelerates fracture repair directly to the fracture site.

Targeting Ligand

  • Oligopeptide – high affinity for bone damage selected

Ligand Linker

  • Connecting the targeting ligand and the therapeutic agent

Therapeutic Agent

  • Anabolic selected

How it works

We connect tissue-specific targeting molecules to approved drugs, biologics or radionuclides via small biological linker molecules. The result is the delivery of the proven therapeutic payload directly to the site of disease or injury.

Ligand Linker

Binding agent connecting the Targeting ligand and the therapeutic agent.

Target Ligand

Binding agent connecting the Targeting ligand and the therapeutic agent.

Therapeutic Agent

  • 70+ compounds tested In Vivo
  • Parathyroid hormone family (Forteo/Tymlos)

Engineered ligands maximize the healing response

Targeting Bone Fractures

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

Targeting Osteogenesis

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.

How it Works

We direct proven treatment therapies to the bone injury site by providing proteins with instructions on where to deploy the therapeutic payload

Move your cursor over the ligand to see details

Ligand Linker

Binding agent connecting the Targeting ligand and the therapeutic agent.

Therapeutic Agent

  • 70+ compounds tested In Vivo
  • Parathyroid hormone family (Forteo/Tymlos)

Target Ligand

Binding agent connecting the Targeting ligand and the therapeutic agent.
Targeting Ligand
Linker

TARGETING LIGAND

  • 25+ compounds tested In Vivo
  • Oligopeptide – high affinity for bone damage
Therapeutic Agent

PAYLOAD

  • 70+ compounds tested In Vivo
  • Parathyroid hormone family (Forteo/Tymlos)